ct041
carsgen therapeutics
['ct041', 'car t', 'carsgen']
carsgen therapeutics (stock code: presented two posters with study results for ct041, an autologous car t-cell product candidate against protein claudin18.2 (cldn18.2) at asco 2022. 
General business news from PR Newswire.